Overview

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Status:
Completed

Trial end date:
2017-07-10

Target enrollment:

Participant gender:

Summary

This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Bococizumab